Blood cancers, High grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Results
Phase 2
This study looked at blinatumomab for people who had fast growing lymphoma that had come back or stopped responding to treatment.
People could join the study between 2017 and 2018. The team published the results in 2020.
There is a link to more information in the ‘Summary of results’ section below.
Recruitment start: 23 January 2017
Recruitment end: 15 January 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Andrew McMillan
Amgen
Last reviewed: 09 Oct 2026
CRUK internal database number: 14674